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41 
ABSTRACT 42 
Eukaryotic ATP-dependent phosphofructokinases (PFKs) are often considered unidirectional 43 
enzymes  catalysing the transfer of a phospho moiety from ATP to fructose 6-phosphate (F6P) to 44 
produce ADP and fructose 1,6-bisphosphate (F16BP). The reverse reaction is not generally 45 
considered to occur under normal conditions and has never been demonstrated for any eukaryotic 46 
ATP-dependent PFKs, though it does occur in PPi-dependent PFKs and has been experimentally 47 
shown for bacterial ATP-dependent PFKs. Evidence is provided via two orthogonal assays that all 48 
three human PFK isoforms can catalyse the reverse reaction in vitro, allowing determination of kinetic 49 
properties. Additionally, the reverse reaction was shown possible for PFKs from three clinically 50 
important trypanosomatids; these enzymes are contained within glycosomes in vivo. This 51 
compartmentalisation may facilitate reversal, given the potential for trypanosomatids to have an 52 
altered ATP/ADP ratio in glycosomes compared to the cytosol. The kinetic properties of each 53 
trypanosomatid PFK were determined, including the response to natural and artificial modulators of 54 
enzyme activity. The possible physiological relevance of the reverse reaction in trypanosomatid and 55 
human PFKs is discussed. 56 
INTRODUCTION 57 
Phosphofructokinase (PFK) catalyses the phosphorylation of fructose 6-phosphate (F6P) to fructose 58 
1,6-bisphosphate (F1,6BP) and plays a central role in the glycolytic pathway of prokaryotes and 59 
eukaryotes.  The enzymatic step catalysed by PFK is conserved in most organisms from Eukarya, 60 
Bacteria and Archaea. Despite an enzyme mechanism that has been conserved for over 2 billion 61 
years, different PFK families have evolved interestingly diverse regulatory mechanisms associated 62 
with considerable differences in protein sequence and architecture. There is increasing interest in 63 
PFK as a drug target in human diseases, including diabetes (1) and cancer (2,3).  Additionally, 64 
glycolysis is a valid therapeutic target for killing pathogens that rely exclusively on glucose catabolism 65 
for their ATP supply; previous work has shown the effectiveness of this approach against 66 
trypanosomatid parasites (4). PFKs from the three trypanosomatid species that cause significant 67 
mortality and morbidity: Trypanosoma brucei (Human African Trypanosomiasis), T. cruzi (Chagas 68 
disease), and Leishmania spp. (Leishmaniasis) are all potential drug targets. 69 
70 
Two main evolutionary groups of PFK are distinguished by their phospho-donor substrates. The 71 
pyrophosphate-dependent group uses inorganic pyrophosphate (PPi) as the phospho donor and is 72 
found in plants and certain protists, including amoeba and bacteria.  The second group uses ATP as 73 
the phospho donor and is found in many other bacteria and protists, plants, and all vertebrates (note 74 
that plants usually contain PFKs from both groups).  Phylogenetic and structural analyses 75 
demonstrate that the two groups evolved from a common ancestor, though amino acid sequence 76 
identities are low (~25%) (5). Despite these differences, there are similarities in catalytic mechanism; 77 
in one interesting case the PPi-PFK of Entamoeba histolytica, which has a 10
6 
fold preference for78 
inorganic pyrophosphate over ATP, could be converted to an ATP-dependent enzyme by a single 79 
mutation (6). This supports the idea that the ATP-dependent PFKs are the primordial form from which, 80 
on multiple occasions, the PPi-dependent enzymes evolved. However, the evolutionary path is 81 
complex, with amino acid sequence comparisons suggesting the ATP-dependent PFK found in 82 
trypanosomatids developed through an ancestral PPi reliant stage before switching back to ATP as a 83 
substrate (7,8). 84 
85 
A biochemically important distinction between the two families is that all PPi-PFKs readily carry out 86 
both the forward and reverse enzyme reactions under physiological conditions. The biological 87 
consequence is that organisms that use PPi-dependent PFKs for the most part do not require 88 
fructose-1,6-bisphosphatase enzymes to carry out the reverse dephosphorylation step required in the 89 
gluconeogenic pathway. Possibly because of its ability to carry out the reaction in both directions, the 90 
PPi-PFK family shows little evidence of allosteric regulatory mechanisms controlling enzyme activity, 91 
though this is not universal  (9).  In contrast, ATP-dependent PFKs have evolved a wide range of 92 
allosteric mechanisms, with associated differences in protein chain lengths and architecture.  93 
94 
The active form of bacterial ATP-dependent PFKs is a homo-tetramer with subunits of approximately 95 
35 kDa. In yeasts, a gene duplication/fusion event yielded double-size chains and these subsequently 96 
underwent additional duplications to give an octamer comprised of homologous catalytic and 97 
regulatory subunits each with a molecular mass of 110-120 kDa (10).  Mammals have tetrameric 98 
PFKs, with subunits of 85 kDa. The N-terminal half of the double enzyme was constrained to retain 99 
the catalytic function, while the substrate binding sites of the C-terminal half evolved into effector 100 
binding sites (11). Higher levels of regulation in mammals are also achieved by three distinct isoforms 101 
with varying properties (denoted as PFK-M, PFK-L and PFK-P) which are expressed in a tissue-102 
specific pattern (12). Trypanosomatid PFKs are intermediate in size (~55kDa); these are strictly ATP 103 
dependent but have amino acid sequences closer to the PPi family and can therefore be regarded as 104 
chimeras. X-ray structures of trypanosomatid PFKs show major differences compared with other ATP-105 
dependent PFKs;  in particular, the C-terminal extensions can form long helices, acting as reaching 106 
arms to hold the tetramer together (8). 107 
108 
Structural differences between ATP-dependent PFKs derive from varying requirements for allosteric 109 
regulation. The smaller bacterial ATP-dependent PFKs are activated by ADP and GDP alone (13) 110 
with  Escherichia coli PFK used in a definitive study by Monod and co-workers to support the now 111 
classic allosteric model of enzyme kinetics (14).  In trypanosomatid PFKs AMP is the only known 112 
activator while in human PFKs the non-catalytic C-domain of each isoform binds the allosteric 113 
activators AMP, ADP and fructose 2,6-bisphosphate (F26BP) (15). 114 
115 
The evolution of these tightly regulated allosteric effector systems in the ATP-dependent PFK family 116 
contrasts with the less regulated bi-directional activity of the PPi-dependent family. For the ATP-117 
dependent PFKs the forward enzymatic reaction is favoured under physiological conditions, often 118 
being regarded as an essentially irreversible reaction under normal conditions. Indeed, the reverse 119 
reaction (F16BP + ADP  F6P + ATP) has never been demonstrated for any eukaryotic ATP-120 
dependent PFK, including any of the human isoforms, in vitro or in vivo. In this paper we demonstrate 121 
that the reverse reaction is possible under experimental conditions for all three human PFK isoforms 122 
and the three trypanosomatid PFK orthologues, and present the kinetic properties for these reactions. 123 
The results suggest that the reverse reaction could occur under certain physiological conditions. 124 
METHODS 125 
The identity of all recombinant PFKs was confirmed by SDS-PAGE showing highly pure PFKs of 126 
expected molecular weights (Figure 1). Additionally, western blots and MALDI-TOF mass 127 
spectrometry using a Bruker Ultraflex instrument confirmed protein identities (data not shown). 128 
129 
Production of trypanosomatid phosphofructokinases 130 
N-terminally His6-tagged trypanosomatid PFK DNA sequences, codon optimised for E. coli131 
expression, were inserted into pET28a or pDEST17 expression plasmids. The recombinant plasmids 132 
were used to transform chemically competent E. coli cells which were grown on LB agar plates with 133 
corresponding antibiotic (Table 1). Single colonies were inoculated into 500ml media in 2L conical 134 
flasks and grown in a shaking incubator at 250 rpm and 37°C to an OD600nm 0.8-0.9, then cold 135 
shocked at 4°C for 30 min.  PFK expression was induced with 1mM isopropyl β-D-1-136 
thiogalactopyranoside (IPTG) for 16h at 100 rpm and 18°C before harvesting the cells via 137 
centrifugation and removal of supernatant.  138 
139 
Cell pellets from 1L cultures were suspended in 50ml lysis buffer (50 mM TEA, 5 mM MgCl2, 50 mM 140 
KCl, 10% glycerol, pH 7.4), supplemented with Roche cOmplete™ EDTA-free Protease Inhibitor 141 
Cocktail and ~5mg bovine pancreas deoxyribonuclease [Sigma-Aldrich D5025]) and lysed with 142 
Constant Cell Disruption Systems at 25kPsi and centrifuged. Filtered supernatant was loaded onto a 143 
cobalt-charged HiTrap 1ml FF immobilized metal affinity chromatography (IMAC) column (GE 144 
Healthcare) equilibrated in wash buffer (50 mM triethanolamine (TEA), 300 mM NaCl, 20 mM 145 
imidazole, 10% glycerol, pH 8.0) in a GE Healthcare ÄKTA purifier system at 6°C. Impurities were 146 
removed by further wash buffer steps with gradually increasing imidazole concentrations before PFK 147 
eluted with elution buffer (50 mM TEA, 300 mM NaCl, 500 mM imidazole, 10% glycerol, pH 8.0). T. 148 
brucei and T. cruzi PFK (TbPFK and TcPFK) eluates were loaded onto a HiPrep Sephacryl™ S-200 149 
16/60 column (GE Healthcare), pre-equilibrated with gel filtration buffer (20 mM TEA, 5 mM MgCl2, 50 150 
mM KCl, 10% glycerol, pH 7.4) and tetrameric fractions eluted with 1.5 column volumes (CV) of gel 151 
filtration buffer. Leishmania infantum PFK (LmPFK) IMAC eluates were loaded onto a HiPrep 26/10 152 
Desalting column (GE Healthcare) pre-equilibrated with gel filtration buffer and eluted using 1.5 CV 153 
gel filtration buffer. Samples were concentrated to 1mg/ml with Vivaspin® 20ml 30,000kDa Molecular 154 
Weight Cut-Off (MWCO) spin concentrators. Aliquots were flash-frozen and stored at -80°C until 155 
required. Tag removal was attempted but only partially successful (Figure 1A); tagged protein was 156 
therefore used. 157 
158 
Production of human phosphofructokinases 159 
Plasmid pJJH71 (16) containing yeast codon optimised cDNA for His6-tagged PFK-M1, PFK-L1, or 160 
PFK-P1 was used to transform PFK-deficient S. cerevisiae (16) via electroporation which were 161 
subsequently grown on YPDA (yeast extract, peptone, dextrose, adenine broth) agar plates. Colonies 162 
were transferred to 2L conical flasks containing 500ml YPDA medium with 50µ/ml carbenicillin and 163 
cultures grown using an Infors HT Multitron standard shaking incubator at 30°C and 250rpm before 164 
harvesting the yeast via centrifugation and removal of supernatant.  165 
 166 
Cell pellets from 2L cultures were suspended in lysis buffer (50mM TEA, 300mM KCl, 10mM 167 
imidazole, 1mM TCEP, 1mM ATP/F6P) supplemented with Roche cOmplete™ EDTA-free Protease 168 
Inhibitor Cocktail and ~5mg bovine pancreas deoxyribonuclease) at 8% w/v and lysed with Constant 169 
Cell Disruption Systems at 40kPsi and centrifuged. Filtered supernatant was loaded onto a nickel-170 
charged HiTrap 1ml FF IMAC column equilibrated in wash buffer (50mM TEA, 300mM KCl, 10mM 171 
imidazole, 1mM TCEP (tris(2-carboxyethyl)phosphine), 1mm ATP/F6P, 10% glycerol) in an ÄKTA 172 
purifier system at 6°C. Impurities were removed by further wash buffer steps with gradually increasing 173 
imidazole concentrations before PFK eluted with elution buffer (50mM TEA, 300mM KCl, 500mM 174 
imidazole, 1mM TCEP, 1mM ATP/F6P). PFK-M was further purified using a GE Healthcare HiPrep 175 
Sephacryl S300 16/600 size-exclusion chromatography column pre-equilibrated with gel filtration 176 
buffer (50mM TEA, 500mM KCl, 5mM MgCl2, 1mM TCEP, 1mM ATP/F6P, 10% glycerol).  For PFK-L 177 
and PFK-P a GE Healthcare Superose 6 10/300 size-exclusion column was used. Samples 178 
corresponding to tetrameric protein (340kDa) were pooled and concentrated using a pre-equilibrated 179 
20ml 30,000kDa MWCO spin concentrator to above 0.3mg/ml. Aliquots were flash-frozen and stored 180 
at -80°C until required. All buffers were at pH 8, except for PFK-M purifications (pH 7.4).  181 
 182 
Demonstration of reverse reaction using an endpoint assay 183 
The Promega Kinase-Glo ATP assay system (V6713) was used to measure ATP production in the 184 
reverse PFK reaction. Energy of the ATP produced was converted to light via the luciferase/luciferin 185 
reaction in an endpoint reaction. 10μl of PFK at 2μg/ml was added to 100μl assay buffer (50mM TEA, 186 
10mM MgCl2, 0.1% w/v BSA, 0.005% TWEEN20, 1% DMSO, pH 7.4) containing 5mM ADP in a white 187 
non-binding 96-well plate. Incubation was carried out at 4°C for 20min, followed by 10min at room 188 
temperature. 5mM F16BP (final concentration) was added and the plate was then centrifuged at 189 
1000rpm for 30 seconds, and further incubated at room temperature for 60 min. 25μl of the “Kinase-190 
Glo reagent” was added to each well for a final incubation period of 30min. Assay output was 191 
measured as luminescence using a Molecular Devices Spectramax M5 Multi-Mode Plate Reader and 192 
converted to ATP concentrations using control data from a constructed ATP titration curve. 193 
 194 
Determination of kinetic characteristics using an enzyme-linked kinetic assay 195 
Conversion of F16BP (Sigma F6803) and ADP (Sigma A4386) to F6P and ATP was measured using 196 
an enzyme-linked assay. F6P was converted to glucose 6-phosphate (G6P) by phosphoglucose 197 
isomerase (PGI), and subsequently to 6-phosphogluconolactone by glucose-6-phosphate 198 
dehydrogenase (G6PD), with concurrent reduction of NAD
+
 to NADH. Formation of NADH was 199 
measured via absorbance of UV at 340nm.  ATP produced was re-converted into ADP by glycerol 200 
kinase (GK) (in the presence of glycerol) to keep the ATP/ADP ratio low.  201 
 202 
15l of assay buffer (50mM TEA, 100mM KCl, 10mM MgCl2, 1mM TCEP, 10% glycerol, pH 7.4) was 203 
added to 40l of assay mix (NAD
+
 (Sigma NAD100-RO), G6PD (Sigma G8529), PGI (Sigma P9544), 204 
and GK (Sigma G6142), then 20l of ADP titration (or 15mM ADP stock) in a clear 96-well plate. The 205 
plate was incubated at 25C for 2min. 5l of 0.2mg/ml PFK was added and the reaction initiated with 206 
20l F16BP titration (or 25mM F16BP stock). UV absorbance at 340nm was measured at 13s 207 
intervals for 15min in a Molecular Devices Spectramax M5 Multi-Mode Plate Reader at 25C. 208 
 209 
Time-dependent absorbance change was converted into rate of NADH oxidation (μM.s
-1
) or specific 210 
activity (μmol.min
-1
.mg
-1
) using the Beer-Lambert law (molar extinction co-efficient of NADH 6.22mM
-211 
1
.cm
-1
). Reaction rates for each well were calculated using an 8-point (104s) rolling average. Kinetic 212 
parameters of the steady-state stage of the reaction were determined with GraphPad Prism 7. Non-213 
linear regression analysis was performed on substrate titration data, with curves fitted using allosteric 214 
sigmoidal models, enabling determination of kinetic values.  215 
RESULTS 216 
 217 
Proof of concept for reversal of direction of PFK reaction 218 
Proof of concept for reversal of the direction of the PFK reaction was established with the ‘Kinase-219 
Glo’® assay. Figure 2 shows that addition of PFK to F16BP and ADP enabled much greater 220 
production of ATP than in control samples alone.  Conversion from concentrations in µg/ml to molar 221 
concentrations shows that human and trypanosomatid PFKs produce similar amounts of ATP per 222 
mole.  The yield of ATP from control experiments may derive from spontaneous conversion of ADP 223 
into ATP occurring at high ADP concentrations (2ADP  ATP + AMP). Potential contamination of 224 
ADP stocks with ATP was prevented by using Ultrapure ADP (>99% purity; Promega). Minimal 225 
concentrations of ATP were present in PFK stocks, as shown by control experiments without F16BP 226 
or ADP; amounts were insufficient to confound results (data not shown). 227 
 228 
Kinetic properties for reverse activity by trypanosomatid PFKs 229 
An enzyme-linked assay was used to measure F6P production from the reverse reaction catalysed by 230 
PFK isoforms. Michaelis-Menten curves using allosteric sigmoidal models were generated for ADP 231 
titrations (Figure 3A) and F16BP titrations (Figure 3B). TbPFK is the most active isoform, with the 232 
lowest K0.5
ADP
 and K0.5
F16BP
(K0.5 defined as concentration of substrate at which half maximal enzyme 233 
velocity is reached, analogous to Michaelis-Menten constant [KM]). TcPFK has similar kinetic 234 
parameters to TbPFK. LmPFK has a slightly lower Vmax and markedly lower affinities for both 235 
substrates, in keeping with known lower activities in the forward reaction (17). Full kinetic parameters 236 
are listed in Table 2. Control experiments without PFK did not produce significant quantities of ATP 237 
(data not shown).  238 
 239 
Both TcPFK and TbPFK reverse reaction kinetics were consistent with allosteric sigmoidal models for 240 
F16BP titrations and for ADP titrations, with LmPFK reaction kinetics showing no statistical difference 241 
between the Michaelis-Menten and allosteric sigmoidal models; the allosteric sigmoidal model was 242 
preferred to retain consistency. 243 
 244 
The reverse PFK reaction can be allosterically modulated in trypanosomatid PFKs 245 
AMP is a known activator, and sole physiological allosteric effector, of the forward PFK reaction in 246 
trypanosomatids (15). The effect of AMP on the reverse activity of trypanosomatid PFKs was 247 
assessed using the enzyme-linked kinetic assay described above. All three trypanosomatid PFKs 248 
were activated in the presence of 0.5mM AMP, with the kcat/K0.5
F16BP
 value increasing two-fold for 249 
TbPFK and TcPFK, and ten-fold for LmPFK (Supplementary Figure 1 and 2). F26BP, a potent 250 
activator of the forward reaction in many eukaryotic ATP-dependent PFKs (but not trypanosomatids) 251 
and bi-directional PPi-dependent plant PFKs (18) did not have any effect at 1mM concentration.  252 
 253 
A series of allosteric inhibitors deriving from a compound with anti-TbPFK activity (4) were tested for 254 
effects on the reverse PFK reaction catalysed by trypanosomatid PFKs. These compounds inhibited 255 
the reverse trypanosomatid PFK reaction with similar potencies to the forward reaction (results not 256 
shown).  257 
 258 
The reverse PFK reaction in human PFK isoforms 259 
Kinetic parameters for human PFK isoforms were determined using the enzyme-linked kinetic assay. 260 
Michaelis-Menten curves using allosteric sigmoidal models were generated for ADP titrations (Figure 261 
4A) and F16BP titrations (Figure 4B). PFK-M and PFK-L have similar Vmax values, but PFK-P is much 262 
less active. However, PFK-L has much lower affinities for ADP and F16BP than the other isoforms, 263 
with the highest K0.5
ADP
 and K0.5
F16BP
 (K0.5
ADP
 for PFK-P not determined). Kinetic parameters are listed 264 
in Table 3. Human PFK isoforms were purified in the presence of 1mM ATP, likely degrading to ADP 265 
over time; human PFK stocks thus contributed 10-40M extra nucleotide (ATP or ADP) to the assay. 266 
Each reaction was therefore normalised against a control reaction that included PFK isoform sample 267 
but not exogenous substrate. 268 
 269 
All reverse reaction kinetics are consistent with allosteric sigmoidal models both for F16BP titrations 270 
and ADP titrations; PFK-M ADP titrations did not show any statistically significant difference between 271 
the two models so the allosteric sigmoidal model was preferred to retain consistency. The reaction 272 
obeys allosteric sigmoidal models at ADP concentrations up to 2.5mM.  273 
 274 
PFK-L has low affinity for ADP and F16BP, indicating a reduced propensity for the reverse reaction 275 
compared to other isoforms. The sequence identities between the three isoforms range from 68 to 276 
71%, with the ATP binding site being 85-90% identical (the F6P binding site has not been fully 277 
characterized as yet). It is challenging to interpret these differences in reverse kinetic properties given 278 
the lack of precise information about isoform specific tissue locations, with much of the original 279 
published data being measured from relatively crude tissue extracts.  However, assuming the original 280 
conclusions reached in the 1970-80s (19) are broadly accurate in stating that PFK-L is highly 281 
expressed in liver tissues (hence the name: PFK-Liver) then the relative inability of PFK-L to catalyse 282 
the reverse reaction may relate to the highly gluconeogenic – and FBPase rich - environment in the 283 
human liver. The relatively low activity of PFK-P was also observed in the forward reaction (not 284 
shown) and may be an intrinsic property resulting from its susceptibility to time and concentration 285 
dependent inactivation probably caused by dissociation of the active tetrameric form (20), 286 
 287 
Substrate inhibition of the reverse PFK reaction in human PFK isoforms 288 
There is an inhibitory effect at higher concentrations of ADP (above 2mM) for PFK-M, but the effect is 289 
not as clearly demonstrated for the other isoforms (Figure 4A). This effect can be seen more clearly 290 
when higher concentrations of ADP are investigated (Figure 5). A similar effect is observed at higher 291 
concentrations of F16BP (above 5mM) for PFK-M (Figure 4B). Standard Michaelis-Menten or 292 
allosteric sigmoidal kinetic models should be used with caution when substrate inhibition is present; 293 
however, more complex models did not increase accuracy of data fitting. It is likely that substrate 294 
inhibition of the reverse PFK reaction is also present in PFK-L and PFK-P at higher substrate 295 
concentrations than were used experimentally but to varying degrees, in a similar way that ATP-296 
dependent inhibition differentially affects the forward reaction in each isoform (21). The rationale for 297 
substrate inhibition of the reverse reaction remains uncertain. It may be analogous to substrate 298 
inhibition by ATP in the forward reaction, which enables finer control of the glycolytic flux (22), though 299 
it would be surprising if such an effect had been evolutionary advantageous given the presumed small 300 
effect on fitness of precise control of the reverse reaction. High ADP/ATP ratios may enable sufficient 301 
ATP production to allow the forward reaction to occur simultaneously; this possibility was reduced – 302 
but necessarily eliminated - by adding an excess of glycerol kinase in the presence of glycerol.   303 
DISCUSSION 304 
 305 
The experiments presented in this paper provide the first kinetic data on the reverse PFK reaction by 306 
eukaryotic ATP-dependent phosphofructokinases.  The basis for the doctrine that PFK acts only in a 307 
forward direction derives from ΔG
o
 being highly favourable for the forward reaction. 308 
 309 
[1] F6P + ATP = F1,6BP + ADP   310 
   311 
ΔG
o
 = -3.4 kcal.mol
−1
 as calculated from the free energies of formation for the products under 312 
standard conditions and 1M concentrations (23). The free energy of the reaction under different 313 
cellular conditions can be estimated from [2], where the reaction quotient Q is the ratio of 314 
concentrations of available products and reactants [3]. 315 
 316 
[2] ΔG = ΔG
o
 + RT ln Q 317 
[3] Q = [ADP].[F16BP]/[ATP].[F6P] 318 
 319 
Estimated cellular concentrations of reactants and products for human and trypanosomes are given in 320 
Table 4 and can be used to calculate the reaction quotients (Q), the free energy (ΔG), and the 321 
equilibrium constant (K), for the PFK reaction in each of the tissue types.  For the reverse PFK 322 
reaction [1] to take place, G needs to be greater than 0: (ΔG
o
 + RT ln Q > 0). Substituting 323 
appropriate values (ΔG
o
 = -3.4 kcal.mol
−1
 and RT= 0.543 kcal.mol
−1
) we can solve for reaction 324 
quotient Q ([ADP].[F16BP]/[ATP].[F6P]) to show that Q must be greater than 500. In other words, a 325 
net reverse reaction will only be energetically favourable when the relative concentration of products 326 
(F16BP & ADP) is at least 500-fold greater than that of the substrates (F6P & ATP). 327 
 328 
As shown in Table 4, the concentrations of substrates and products measured in different cell types 329 
give estimated reaction quotients of 0.07-0.85 in human tissues and 0.4 in trypanosomatid 330 
glycosomes. Additional experimental measurements of muscle from various species, including 331 
insects, fish and mammals give ATP/ADP ratios ranging from 11:1 to 1:1 and an average reaction 332 
quotient (Q) of 0.42 for their PFKs (24).  These Q low values show that in most organisms PFK is 333 
working far from the reaction’s equilibrium.  Further  experimental studies using mass spectrometry to 334 
estimate forward and reverse flux of each step in glycolysis in yeast, E. coli and a mammalian kidney 335 
cell line (25) identified PFK as an almost exclusively forward driven glycolytic step in all cells. The 336 
measured ΔG = -3.2 kcal.mol
−1
 for PFK in the kidney cell estimated the reverse flux of PFK to be less 337 
than 0.7% of the forward flux, with the authors concluding that (under steady state conditions with 338 
cells grown in high glucose media) “phosphofructokinase functions as a classic irreversible step”. Our 339 
data show that for human cells, the measured K0.5
ADP
 values for the reverse reaction (Table 3) 340 
exceeds the cytosolic concentrations of ADP (Table 4), but as steady-state concentrations of F16BP 341 
are lower than the K0.5
F16BP
 values, it seems likely that under steady state conditions the reverse 342 
reaction would indeed be inefficient.   However cells can be subjected to extreme conditions of stress 343 
and nutrient deprivation and the PFK reverse flux may be very different in non-steady state, glucose-344 
poor conditions and Q values of 500 or above could easily be achieved if ATP or G6P were 345 
(transiently) depleted.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    346 
 347 
Despite the apparently high energetic barrier, the reverse reaction for ATP-dependent PFK is possible 348 
in cells under certain conditions.  Experimentally, the reverse reaction was first shown in vitro in E. 349 
coli PFK at high ADP and F16BP concentrations (26). Kinetic parameters were determined as KM
F16BP
 350 
of 398μM at 2mM ADP and KM
ADP
 50μM at saturating concentrations of F16BP. The kinetic 351 
parameters suggest generally tighter F16BP and ADP binding compared with the PFK isoforms 352 
presented here (Tables 2 and 3) but are not far removed from the kinetic values for PFK-M and this 353 
leaves open the question whether there are ever cellular conditions when the reverse reaction could 354 
occur.  355 
 356 
Metabolite concentrations vary widely between individuals (27) and these differences will be 357 
exaggerated further under conditions of metabolic stress.  Low concentrations of aldehyde severely 358 
deplete ATP levels (28);   cells infected with viruses (29) and necrotic cancer cells (30) have also 359 
shown large variations in ADP:ATP ratios. Cells also undergo programmed responses when adapting 360 
to new states invoked by events including cell division, apoptosis or nutritional stress which involve 361 
concerted changes in activities for families of enzymes (so called ‘allostatic changes’) (31). The 362 
transition between these states frequently necessitates large swings in metabolite concentrations. 363 
One such example is the transition from glycolysis to gluconeogenesis triggered by large changes in 364 
the ATP:ADP ratio. There will be a lag period whilst waiting for upregulation of FBPase (the 365 
gluconeogenic protein that carries out the reverse PFK reaction but not coupled to ATP formation) by 366 
increasing transcription/translation or by post-translational modification. During this lag period we 367 
postulate that substrate concentrations may be sufficiently perturbed to permit PFK reversal, before 368 
FBPase activity becomes available. The potential role of the PFK filament assemblies (35) and the 369 
existence of the as yet poorly characterised glycosome complex (36) or G-bodies (32) that tunnel 370 
substrates with potentially very high effective concentrations also provides a mechanism for achieving 371 
non-equilibrium concentrations of substrates sufficient to push PFK into reverse.    372 
 373 
Trypanosomatids have a uniquely interesting way of organising the glycolytic enzymes with the first 374 
seven enzymes in the pathway (including PFK) sequestered in glycosomes (33). In the bloodstream 375 
form of T. brucei, there can be over 60 of these organelles per cell, comprising about 5% of the cell 376 
volume  (34).   Metabolism in the T. brucei parasite has been extensively studied and kinetic 377 
parameters for the glycolytic enzymes have been incorporated into a sophisticated in silico, 378 
experimentally validated metabolic model (35,36). Despite the good predictive properties of such 379 
models, it remains difficult to determine the concentrations of individual metabolites. A potential 380 
complication in parameterising in silico models is caused by compartmentalisation in eukaryotic cells, 381 
as metabolite concentrations may vary significantly between different types of vesicles.   382 
 383 
An experimental indication that the reverse PFK reaction may be physiologically relevant and play a 384 
role in gluconeogenesis in trypanosomes comes from 
13
C labelled glucose LC-MS work in 385 
bloodstream forms of T. brucei (37). This showed that hexose phosphates can indeed be derived 386 
(albeit at a low rate of 2%) from F16BP despite no active form of FBPase being detectable in 387 
glycosomes thus possibly indicating reversal of the normal PFK reaction direction. Further 388 
biochemical studies suggest that gluconeogenesis occurs after complete knock-out of FBPase 389 
(F.Bringaud, personal communication) and leaves open the possibility that the reverse PFK reaction 390 
may contribute to this pathway.  Gluconeogenesis is also carried out in Leishmania, but recent studies 391 
(38) showed that Leishmania amastigotes in activated macrophages cannot use amino acids, instead 392 
relying on glycolysis.    It is unlikely that FBPase is active in amastigotes in vivo, because as this 393 
would lead to ATP loss by futile cycling. A likely scenario is that these leishmanial forms have an 394 
inactivated form of FBPase (e.g. by posttranslational modification), and like the bloodstream-form T. 395 
brucei in the presence of abundant glucose, PFK may function in reverse.  As for mammalian PFK, 396 
the estimated physiological reaction quotient of 0.4 (Table 4) is far below the required reaction 397 
quotient (500) for the reverse direction. Nevertheless, measuring accurate intra-glycosomal substrate 398 
concentrations is technically difficult, meaning that the in vivo reaction quotient inside glycosomes 399 
may be significantly different from whole cell data.  An analogous situation occurs with the T. brucei 400 
glycosomal glycerol kinase reaction, for which it is known that reversal occurs in vivo with a low 401 
ATP/ADP ratio in the organelles (as created under anaerobic conditions) in the presence of glycerol 402 
3-phosphate despite the G° being even less favourable than for PFK reversal (39). Furthermore, 403 
mutagenesis experiments revealed structural optimisation of this enzyme for catalysis of the reverse 404 
reaction (40).   405 
 406 
Our work shows that LmPFK has significantly lower affinities for ADP and F16BP in the reverse 407 
reaction compared to the other trypanosomatid PFKs, though it is activated much more by AMP. The 408 
rationale for the differences in trypanosomatid PFK kinetic properties may derive from the differing 409 
nutritional environments to which each parasite has become adapted. T. brucei is exclusively extra-410 
cellular, usually confined to the haemolymphatic circulation and cerebrospinal fluid, whereas T. cruzi 411 
is both (transiently) bloodstream and intracellular (cytosolic), infecting a wide variety of cells. 412 
Leishmania parasites are predominantly restricted to macrophage phagolysosomes, where they may 413 
become metabolically quiescent resulting in low growth rates (41). In this energy restricted 414 
environment, the low-energy signal of rising AMP levels may be more important in stimulating 415 
glycolytic or gluconeogenic activity, accounting for the greater sensitivity of LmPFK to AMP. 416 
 417 
The kinetic data for the eukaryotic ATP-dependent PFKs presented in this paper help provide a more 418 
detailed understanding of the controls governing the glycolytic and gluconeogenic pathways. They will 419 
also provide useful experimental data to feed into the increasingly detailed computational models 420 
describing these pathways in mammals (42) and trypanosomes (43). The high reaction quotient (Q) 421 
required for the reverse reaction can in principle be attained when ATP has been depleted (< 100µM) 422 
in the presence of physiologically relevant cellular concentrations of ADP, F6P and F16BP.  However, 423 
for the human isoforms, the measured K0.5 values for F16BP are higher than the measured cellular 424 
concentrations. To suggest any physiological relevance for the human isoforms would require the 425 
existence of an ‘apparent concentration’ of F16BP up to ten-fold higher than has been measured; this 426 
is potentially achievable by invoking substrate tunnelling or metabolon structures. The kinetic data 427 
measured for the trypanosomatid PFKs would (as for the mammalian PFKs) require a significant 428 
increase in ADP/ATP ratio for the reverse reaction, though the cellular concentration of F16BP would 429 
(unlike the mammalian case) be above the K0.5 and sufficient to drive the reaction in the opposite 430 
direction.  Future more detailed metabolomics studies will continue to deliver more precise data on 431 
time-dependent and organelle-dependent metabolite concentrations which will shed more light on the 432 
potential physiological relevance of the reverse PFK reaction.    433 
 434 
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TABLES 
Table 1 Expression conditions for trypanosomatid PFKs in E. coli 
 DNA source 
strain 
Expression 
plasmid 
Expression 
cell line 
Antibiotic Media 
T. b. brucei Lister 427 pET28a C41 (DE3) Kanamycin 2xYT broth 
T. cruzi CL Brener pET28a BL21 (DE3) Kanamycin Superbroth 
L. infantum JPCM5 pDEST17 C41 (DE3) Carbenicillin LB broth 
 
 
  
Table 2 Kinetic parameters for trypanosomatid PFKs in the reverse reaction. Values are mean 
averages (+/- standard error of mean; n = 3). Large standard errors for TcPFK data result 
from varying degree of fit of non-linear regression sigmoidal models, despite narrow error 
bars apparent in Figure 4. 
 Vmax 
(moles/min.mg) 
K0.5
ADP 
(M)
 
K0.5
F16BP 
(M)
 h (ADP) h (F16BP) 
TcPFK 4.77 (1.37) 1768 (2238) 1540 (153) 0.51 (0.14) 1.72 (0.22) 
TbPFK 4.22 (0.28) 1382 (275) 1287 (202) 0.83 (0.07) 0.86 (0.06) 
LmPFK 3.79 (0.69) 3137 (1084) 2495 (624) 1.42 (0.37) 1.71 (0.65) 
 
  
Table 3  PFK-L has the lowest affinity for F16BP in the reverse reaction. (Mean average values with 
SEM values in brackets; n = 3).  
 
Vmax 
(moles/min.mg) 
K0.5
ADP 
(M) K0.5
F16BP 
(M) h (ADP) h (F16BP) 
PFK-M 0.63 (0.05) 66.8 (13.4) 804 (66.1) 0.71 (0.22) 1.83 (0.23) 
PFK-L 0.62 (0.01) 344.9 (36.4) 2100 (78.4) 1.39 (0.17) 2.49 (0.19) 
PFK-P 0.22 (0) ND 717.8 (58.1) ND 1.35 (0.12) 
 
  
Table 4: Concentrations of substrates and products of PFK in various mammalian tissues. ΔG 
calculated from equation (2) using RT = 0.543 kcal.mol
−1
 where R is the gas constant (1.987 
cal.mol
−1
K
−1
) and T = temperature (293K).  Equilibrium constant K is calculated from K = exp (-
ΔG/RT). References for concentrations (directly measured in non-italicised text,  derived from models 
based on whole cell lysate data in italicised text): 
a 
(Minakami and Yoshikawa 1966);
 b 
(Beis and 
Newsholme 1975);
 c 
(Zalitis and Oliver 1967);
 d 
(Lowry and Passonneau 1964);
 e 
(Spolter, Adelman, 
and Weinhouse 1965);
 f 
(Rao and Oesper 1961);
 g 
(Hisanaga, Onodera, and Kogure 1986);
 h 
(Bakker, 
Westerhoff, and Michels 1995);
 i 
(Graven et al. 2014). 
 
 Erythrocyte  Muscle Brain T. brucei glycosome 
[ATP] M  1850
a
 4990
b
 3325
g
 3870
i
 
[ADP] M 180
a
 600
f
 309
g
 1315
i
 
[F6P] M 15.7
a
 110
c
 27
d
 2400
h
 
[F16BP] M 7
a
 32
e
 200
d
 1900
h
 
Q (derived)  0.04 0.03 0.69 0.27 
G (kcal/mol) -5.09 -5.21 -3.6 -4.7 
 
FIGURES 
 
Figure 1. SDS-PAGE gels (4-20%) showing A) trypanosomatid PFKs were produced at high purity but 
removal of tags was only partially successful and B) human PFK isoforms were produced at high 
purity but with anomalous migration of PFK-L. Tagged enzymes were used for all experiments due to 
incomplete tag cleavage and reduction of enzyme activity after cleavage (data not shown), likely 
secondary to conditions required to remove tag. Ladder markers are in kDa. 
 
 
PFK 
PFK 
A B 
Figure 2. ATP is produced by PFKs from ADP and F16BP using an endpoint assay (ADP 5mM, 
F16BP 5mM, error bars are standard deviations; n = 2). 
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Figure 3.  
A) Trypanosomatid PFKs have different kinetic responses for ADP titrations (F16BP 5mM). 
B) Trypanosomatid PFKs have different kinetic responses for F16BP titrations (ADP 3mM). 
(error bars are standard deviations, n = 3). 
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Figure 4. 
A) Human PFK isoforms have different kinetic responses for ADP titrations (F16BP 5mM)
B) Human PFK isoforms have different kinetic responses for F16BP titrations (ADP 3mM)
PFK-P data are missing for 4A due to lack of enzyme stability under these assay conditions. (Error 
bars are standard deviations, n = 3, isoforms were individually normalised to highest specific activity). 
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Figure 5.  High concentrations of ADP inhibit the reverse reaction for PFK-M. (Error bars are standard 
deviations; n = 3). 
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SUPPLEMENTARY FIGURE 1 
A) AMP activates TcPFK with respect to ADP titrations (F16BP 10mM). 0mM AMP (solid 
triangles  with solid line), 0.5mM AMP (open triangles  with dotted line) 
B) AMP activates TbPFK with respect to ADP titrations (F16BP 10mM). 0mM AMP (solid 
squares  with solid line), 0.5mM AMP (open squares  with dotted line) 
C) AMP activates LmPFK with respect to ADP titrations (F16BP 20mM). 0mM AMP (solid circles 
 with solid line), 0.5mM AMP (open circles  with dotted line) 
(n= 2, error bars are standard deviations, results for each enzyme normalised to highest specific 
activity without AMP present).  
 
  

SUPPLEMENTARY FIGURE 2 
A) AMP activates TcPFK with respect to F16BP titrations (ADP 5mM). 0mM AMP (solid triangles
 with solid line), 0.5mM AMP (open triangles  with dotted line)
B) AMP activates TbPFK with respect to F16BP titrations (ADP 5mM). 0mM AMP (solid 
squares with solid line), 0.5mM AMP (open squares  with dotted line)
C) AMP activates LmPFK with respect to F16BP titrations (ADP 10mM). 0mM AMP (solid 
circles with solid line), 0.5mM AMP (open circles  with dotted line)
(n= 2, error bars are standard deviations, results for each enzyme normalised to highest specific 
activity without AMP present).  
  
